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Targeted next-generation 
sequencing of the 16S-23S rRNA 
region for culture-independent 
bacterial identification - increased 
discrimination of closely related 
species
Artur J. Sabat1,2, Evert van Zanten2, Viktoria Akkerboom1, Guido Wisselink2, Kees van 
Slochteren2, Richard F. de Boer2, Ron Hendrix2, Alexander W. Friedrich1, John W. A. Rossen1 & 
Anna M. D. (Mirjam) Kooistra-Smid1,2
The aim of this study was to develop an easy-to-use culture-free diagnostic method based on next 
generation sequencing (NGS) of PCR amplification products encompassing whole 16S-23S rRNA region 
to improve the resolution of bacterial species identification. To determine the resolution of the new 
method 67 isolates were subjected to four identification methods: Sanger sequencing of the 16S rRNA 
gene; NGS of the 16S-23S rRNA region using MiSeq (Illumina) sequencer; Microflex MS (Bruker) and 
VITEK MS (bioMérieux). To evaluate the performance of this new method when applied directly on 
clinical samples, we conducted a proof of principle study with 60 urine samples from patients suspected 
of urinary tract infections (UTIs), 23 BacT/ALERT (bioMérieux) positive blood culture bottles and 21 
clinical orthopedic samples. The resolution power of NGS of the 16S-23S rRNA region was superior to 
other tested identification methods. Furthermore, the new method correctly identified pathogens 
established as the cause of UTIs and blood stream infections with conventional culture. NGS of the 16S-
23S rRNA region also showed increased detection of bacterial microorganisms in clinical samples from 
orthopedic patients. Therefore, we conclude that our method has the potential to increase diagnostic 
yield for detection of bacterial pathogenic species compared to current methods.
Timely, appropriate treatment of infection depends on rapid and specific identification of causative microorgan-
isms. To date, identification of bacterial species highly depends on culture or molecular tests, including 16S rRNA 
gene Sanger sequencing1, 2. Significant limitations of culture methods are that some bacteria are slow-growing or 
fastidious, making identification of them complicated and time and resource consuming3. Although molecular 
tests that target specific microorganisms are more rapid and sensitive than culture methods they need an a priori 
knowledge of the likely pathogenic species that could be present in a sample. If bacteriological identification 
by culture methods fails, Sanger sequencing of the variable 16S rRNA gene is used for identification. The gene 
sequence has been proven to be a reliable genetic marker as it is present in all bacteria and its function has not 
changed over time4. However, unequivocal identification is not always possible due to the high sequence similar-
ities of the 16S rRNA gene in some bacterial species5. Although Sanger sequencing of the 16S rRNA gene can be 
applied directly on clinical materials, in polymicrobial samples it usually cannot identify more than one species 
simultaneously or at least this process is challenging by sorting out the ambiguous signals from mixed chromato-
grams using a computer program6.
1Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, 
The Netherlands. 2Department of Medical Microbiology, Certe, Groningen, The Netherlands. Correspondence and 
requests for materials should be addressed to A.W.F. (email: alex.friedrich@umcg.nl)
Received: 6 March 2017
Accepted: 26 April 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 3434  | DOI:10.1038/s41598-017-03458-6
Sample




Identification of additional 
colonies by culture methods Species content by NGS of 16S-23S rRNA region (% of total reads)
UR1 Pseudomonas aeruginosa 105 Lactobacillus gasseri (97.2%), Pseudomonas aeruginosa (2.4%), Corynebacterium amycolatum (0.4%)
UR2 Proteus mirabilis 104 Proteus vulgaris (70.3%), Proteus mirabilis (29.7%)
UR3 Escherichia coli 105 Escherichia coli (99.1%), Lactobacillus delbrueckii (0.9%)
UR4 Escherichia coli 105 Escherichia coli (99.1%), Peptoniphilus lacrimalis (0.3%), Bacteroides sp. (0.6%)
UR5 Escherichia coli 105 Escherichia coli (93.2%), Undibacterium oligocarboniphilum (6.3%), Pseudomonas saccharophila (0.3%), Phenylobacterium sp (0.2%)
UR6 No clinical significance 104 Bifidobacterium sp Actinobaculum schaalii (100%)
UR7 Escherichia coli 105 Escherichia coli (80.7%), Lactobacillus crispatus (19.3%)
UR8 Escherichia coli 105 Escherichia coli (98.7%), Enterococcus faecalis (1.0%), Aerococcus sanguinicola (0.3%)
UR9
Escherichia coli 105 Escherichia coli (53.7%), Klebsiella oxytoca (43.6%), Staphylococcus aureus 
(2.4%), Enterococcus faecalis (0.3%)Staphylococcus aureus 105
UR10 No clinical significance 102
Ezakiella peruensis (28,6%), Fenollaria massiliensis (4,1%), Helcococcus 
sp. (2,6%), Peptoniphilus duerdenii (2,6%), Mobiluncus curtisii (2,4%), 
Varibaculum cambriense (2,2%), Peptoniphilus harei (1,3%), Actinobaculum 
urinale (0,8%), Peptoniphilus lacrimalis (0,8%), Propionimicrobium sp. 
(0,7%), Facklamia sp. (0,7%), Finegoldia magna (0,6%), Anaerococcus 
obesiensis (0,6%), Anaerococcus prevotii (0,4%), Anaerococcus degenerii 
(0,4%), Actinobaculum sp. (0,4%), Aerococcus urinae (0,3%), Fastidiosipila 
sanguinis (0,2%), Fastidiosipila sanguinis (0,2%), Bacteroides coagulans 
(0,2%), Unidentified species (50,2%)
UR11 No clinical significance 102 Staphylococcus epidermidis No PCR product
UR12 No clinical significance 103 Proteus mirabilis
Proteus mirabilis (75.5%), Proteus vulgaris (17.5%), Undibacterium 
oligocarboniphilum (4.8%), Aerococcus urinae (1.2%), Corynebacterium 
striatum (0.3%), Pseudomonas saccharophila (0.3%), Enterococcus faecalis 
(0.2%), Ralstonia pickettii (0.1%)
UR13 No clinical significance 102 No PCR product
UR14 No clinical significance 102
Undibacterium oligocarboniphilum (36.4%), Fenollaria massiliensis 
(15.6%), Mobiluncus curtisii (10.6%), Peptoniphilus lacrimalis (5.9%), 
Unidentified species (5.3%), Peptostreptococcus anaerobius (4.4%), 
Peptoniphilus koenoeneniae (4.1%), Pseudomonas saccharophila (3.1%), 
Atopobium deltae (3.7%), Candidatus Peptoniphilus massiliensis (2.6%), 
Anaerococcus sp. (1.8%), Jonquetella anthropi (1.1%), Peptoniphilus harei 
(1.1%), Streptococcus anginosus (0.8%), Ralstonia pickettii (0.7%), Dialister 
propionicifaciens (0.6%), Methylobacterium oryzae (0.6%), Asinibacterium 
lactis (0.5%), Methylobacterium jeotgali (0.4%), Peptoniphilus duerdenii 
(0.4%), Fusobacterium nucleatum (0.3%)
UR15 No clinical significance 102 Streptococcus anginosus
Unidentified species (28.3%), Undibacterium oligocarboniphilum (13.1%), 
Peptoniphilus lacrimalis (11.5%), Mobiluncus curtisii (9.5%), Streptococcus 
anginosus (8.3%), Fusobacterium nucleatum (3.8%), Propionimicrobium 
lymphophilum (2.1%), Varibaculum cambriense (2.0%), Dialister sp. 
(1.9%), Atopobium deltae (1.2%), Facklamia hominis (1.1%), Pseudomonas 
saccharophila (1.1%), Dialister propionicifaciens (0.9%), Faecalibacterium 
prausnitzii (0.9%), Parvimonas micra (0.9%), Fenollaria massiliensis (0.9%), 
Prevotella disiens (0.9%), Peptoniphilus harei (0.8%), Actinobaculum 
massiliense (0.7%), Dialister succinatiphilus (0.7%), Gemmiger formicilis 
(0.7%), Corynebacterium pyruviciproducens (0.6%), Mycoplasma 
spermatophilum (0.6%), Actinobaculum sp. (0.5%), Asinibacterium 
lactis (0.5%), Atopobium vaginae (0.5%), Mobiluncus curtisii (0.5%), 
Alistipes onderdonkii (0.4%), Anaerococcus sp. (0.4%), Bacteroides 
massiliensis (0.4%), Anaerococcus lactolyticus (0.3%), Anaerococcus 
obesiensis (0.3%), Anaerococcus prevotii (0.3%), Finegoldia magna 
(0.3%), Methylobacterium jeotgali (0.3%), Peptoniphilus duerdenii (0.3%), 
Peptoniphilus massiliensis (0.3%), Ralstonia pickettii (0.3%), Treponema 
refringens (0.3%), Actinomyces turicensis (0.2%), Bacteroides sp. (0.2%), 
Dialister micraerophilus (0.2%), Eubacterium hallii (0.2%), Peptoniphilus 
koenoeneniae (0.2%), Peptoniphilus obesi (0.2%), Phascolarctobacterium 
succinatutens (0.2%), Porphyromonas bennonis (0.2%)
UR16 No clinical significance 102 No PCR product
UR17 No clinical significance 102
Atopobium deltae (32.6%), Undibacterium oligocarboniphilum (19.4%), 
Lactobacillus iners (16.4%), Unidentified species (10.5%), Peptoniphilus 
coxii (7.5%), Anaerococcus lactolyticus (2.7%), Parvimonas micra 
(2.2%), Peptoniphilus lacrimalis (1.8%), Pseudomonas saccharophila 
(1.6%), Peptoniphilus grossensis (1.0%), Aerococcus christensenii (0.9%), 
Peptoniphilus duerdenii (0.9%), Peptoniphilus harei (0.5%), Actinobaculum 
schaalii (0.4%), Ralstonia pickettii (0.4%), Solobacterium moorei (0.4%), 
Asinibacterium lactis (0.3%), Propionibacterium acnes (0.2%), Varibaculum 
cambriense (0.2%)
UR18 No clinical significance 102 No PCR product
Continued
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Identification of additional 
colonies by culture methods Species content by NGS of 16S-23S rRNA region (% of total reads)
UR19 No clinical significance 102
Undibacterium oligocarboniphilum (28.1%), Sneathia sanguinegens 
(18.3%), Lactobacillus iners (16.5%), Atopobium vaginae (4.3%), Aerococcus 
christensenii (4.0%), Ureaplasma urealyticum (3.5%), Pelomonas 
saccharophila (1.8%), Ralstonia pickettii (1.7%), Megasphaera indica (1.4%), 
Streptococcus anginosus (0.9%), Methylobacterium radiotolerans (0.6%), 
Prevotella amnii (0.6%), Methylobacterium aerolatum (0.5%), Dialister 
micraerophilus (0.4%), Asinibacterium lactis (0.2%), Brevundimonas 
intermedia (0.2%), Unidentified species (16.8%)
UR20 No clinical significance 102 No PCR product
UR21 No clinical significance 102 No PCR product
UR22 No clinical significance 102
Lactobacillus crispatus (78.5%), Undibacterium oligocarboniphilum 
(14.4%), Pseudomonas saccharophila (2.3%), Undibacterium 
ligocarboniphilum (1.5%), Ralstonia pickettii (1.0%), Asinibacterium lactis 
(0.4%), Lactobacillus vaginalis (0.3%), Staphylococcus capitis (0.2%), 
Methylobacterium oryzae (0.1%), Unidentified species (1.3%)
UR23 No clinical significance 102 No PCR product
UR24 No clinical significance 103 Staphylococcus epidermidis, Streptococcus anginosus
Lactobacillus jensenii (98.5%), Finegoldia magna (0.5%), Streptococcus 
anginosus (0.5%), Anaerococcus obesiensis (0.3%), Propionimicrobium 
lymphophilum (0.2%)
UR25 No clinical significance 104
Staphylococcus haemolyticus, 
Proteus mirabilis, Escherichia 
coli
Lactobacillus iners (77.8%), Acinetobacter lwoffii (12.3%), Acinetobacter 
radioresistens (3.8%), Escherichia coli (3.0%), Proteus mirabilis (1.1%), 
Enterococcus faecalis (0.5%), Peptoniphilus harei (0.4%), Streptococcus 
agalactiae (0.4%), Finegoldia magna (0.2%), Proteus vulgaris (0.2%), 
Corynebacterium sp. (0.1%), Pseudomonas stutzeri (0.1%), Streptococcus 
sp. (0.1%)
UR26 No clinical significance 102 Staphylococcus hominis No PCR product
UR27 No clinical significance 102 Staphylococcus hominis
Lactobacillus iners (84.1%), Lactobacillus jensenii (11.1%), Lactobacillus sp. 
(2.8%), Undibacterium oligocarboniphilum (0.9%), Staphylococcus hominis 
(0.5%), Lactobacillus vaginalis (0.2%), Pseudomonas saccharophila (0.2%), 
Asinibacterium lactis (0.1%), Corynebacterium tuberculostearicum (0.1%)
UR28 No clinical significance 103 Enterococcus faecalis, Streptococcus mitis/oralis No PCR product
UR29 No clinical significance 102 No PCR product
UR30 No clinical significance 102 No PCR product
UR31 No clinical significance 102 No PCR product
UR32 No clinical significance 102 Lactobacillus iners (98.6%), Lactobacillus jensenii (1.4%)
UR33 Pseudomonas aeruginosa 105 Pseudomonas aeruginosa (99.7%), Peptostreptococcaceae sp. (0.2%), Anaerococcus degenerii (0.1%)
UR34 Escherichia coli 104 Escherichia coli (100%)
UR35 Escherichia coli 105 Escherichia coli (100%)
UR36 Proteus mirabilis 105 Unidentified species (61.4%), Peptoniphilus harei (18.0%), Proteus mirabilis (16.3%), Aerococcus urinae (4.2%), Staphylococcus aureus (0.1%)
UR37 Escherichia coli 105 Escherichia coli (100%)
UR38 Escherichia coli 105 Escherichia coli (100%)
UR39 Klebsiella pneumoniae 105 Klebsiella pneumoniae (100%)
UR40 Pseudomonas aeruginosa 104 Pseudomonas aeruginosa (100%)
UR41 Klebsiella pneumoniae 105 Klebsiella pneumoniae (100%)
UR42 Escherichia coli 104 Escherichia coli (100%)





UR45 No clinical significance 103
Streptococcus mitis/
oralis, Escherichia coli, 
Staphylococcus aureus, 
Staphylococcus epidermidis
Ureaplasma parvum (42.2%), Prevotella sp. (27.0%), Prevotella bivia 
(10.8%), Anaerococcus lactolyticus (7.7%), Peptostreptococcus anaerobius 
(6.4%), Peptoniphilus sp. (1.7%), Finegoldia magna (1.5%), Streptococcus 
oralis (1.5%), Escherichia coli (0.6%), Lactobacillus crispatus (0.4%), 
Staphylococcus aureus (0.3%)




Enterococcus faecalis (99.7%), Lactobacillus iners (0.3%)





Aerococcus sanguinicola (92,5%), Aerococcus sp. (4,4%), Aerococcus urinae 
(1,8%), Peptoniphilus harei (0,9%), Lactobacillus iners (0,3%)
UR48 Staphylococcus aureus 105 Klebsiella pneumoniae Staphylococcus aureus (99,8%), Escherichia coli (0,2%)
UR49 Staphylococcus epidermidis 105 Staphylococcus epidermidis (97.6%), Staphylococcus sp. (1.3%), Gardnerella vaginalis (1.1%)
UR50 Enterococcus feacalis 105 Enterococcus faecalis (100%)
UR51 No clinical significance 103 Staphylococcus epidermidis Staphylococcus epidermidis (100%)
Continued
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Next generation sequencing (NGS) allows culture free detection of a theoretically unlimited number of path-
ogens and thus provides insight in the full microbiome. Since the introduction of benchtop sequencers, NGS is 
likely to become a diagnostic tool within the next few years in microbiological laboratories3, 7, 8. Metagenomics will 
be the ultimate approach in detecting all microorganisms (e.g. bacteria, viruses, fungi) in a sample. Unfortunately, 
Sample Patient Bottle Culture (Maldi-TOF MS) NGS of 16S-23S rRNA region (% of total reads)
BC01 Patient A anaerobic Escherichia coli Escherichia coli (100%)
BC02 Patient B aerobic Streptococcus dysgalactiae Streptococcus dysgalactiae (100%)
BC03 Patient C anaerobic Klebsiella oxytoca Klebsiella oxytoca (100%)
BC05 Patient D aerobic Staphylococcus heamolyticus Staphylococcus haemolyticus (100%)
BC06 Patient E anaerobic Staphylococcus hominis Staphylococcus hominis (100%)
BC07 Patient F aerobic Staphylococcus capitis Staphylococcus capitis (100%)
BC08 Patient G anaerobic Streptococcus pneumoniae Streptococcus pneumoniae (100%)
BC09 Patient H aerobic Staphylococcus epidermidis Staphylococcus epidermidis (100%)
BC10 Patient H anaerobic Staphylococcus hominis Staphylococcus hominis (100%)
BC11 Patient I anaerobic Bacteroides sp. Bacteroides fragilis (100%)
BC12 Patient J aerobic Staphylococcus hominis Staphylococcus hominis (100%)
BC13 Patient K aerobic Staphylococcus aureus Staphylococcus aureus (100%)
BC14 Patient L aerobic Klebsiella oxytoca Klebsiella oxytoca (100%)
BC15 Patient M anaerobic Streptococcus pneumoniae Streptococcus pneumoniae (100%)
BC16 Patient N aerobic Escherichia coli Escherichia coli (100%)
BC17 Patient O anaerobic Staphylococcus aureus Staphylococcus aureus (100%)
BC18 Patient P anaerobic Streptococcus pneumoniae Streptococcus pneumoniae (100%)
BC19 Patient Q aerobic Escherichia coli, Streptococcus infantis Escherichia coli (69.3%), Streptococcus lutetiensis (30.7%)
BC20 Patient Q anaerobic Escherichia coli Escherichia coli (100%)
BC21 Patient R aerobic Escherichia coli Escherichia coli (100%)
BC22 Patient R anaerobic Bacteroides vulgatus Bacteroides dorei (100%)
BC23 Patient S aerobic Staphylococcus hominis Staphylococcus hominis (100%)
BC24 Patient S aerobic Staphylococcus epidermidis Staphylococcus epidermidis (100%)
Table 2. Bacterial identification results from 23 positive blood culture bottles based on culture and NGS of 16S-
23S rRNA region.
Sample




Identification of additional 
colonies by culture methods Species content by NGS of 16S-23S rRNA region (% of total reads)
UR52 Streptococcus aggalactiae 104 Staphylococcus warneri Actinobaculum schaalii (54.4%), Streptococcus agalactiae (45.6%)
UR53
Escherichia coli 105
Escherichia coli (70.1%), Aerococcus urinae (22.5%), Enterococcus sp. (7.5%)
Enterococcus feacalis 105
UR54
Escherichia coliA 104 Lactobacillus gasseri (53.2%), Escherichia coli (41.8%), Streptococcus 
pasteurianus (4.7%), Enterococcus sp. (0.3%)Escherichia coliA 104
UR55 Klebsiella pneumoniae 105 Klebsiella pneumoniae (74.0%), Actinotignum sanguinis (21.6%), Lactobacillus crispatus (2.6%), Aerococcus urinae (1.8%)
UR56 No clinical significance 102
Eukaryotic DNA (85.0%), Anaerococcus sp. (6.5%), Staphylococcus 
epidermidis (3.3%), Klebsiella pneumoniae (2.6%), Aerococcus urinae 
(1.7%), Escherichia coli (0.8%)
UR57 No clinical significance 102 No PCR product
UR58 No clinical significance 102 Staphylococcus epidermidis
Peptoniphilus sp. (22.1%), Anaerococcus sp. (19.8%), Fusobacterium 
nucleatum (18.5%), Unidentified (17.3%), Streptococcus anginosus (10.8%), 
Dialister sp. (7.3%), Aerococcus urinae (2.0%), Sneathia sp. (0.6%), 
Lactobacillus iners (0.4%), Lactobacillus sp. (0.4%), Dialister micraerophilus 
(0.4%), Fenollaria sp. (0.4%)
UR59 Klebsiella pneumoniae 105 Klebsiella variicola (89.4%), Klebsiella sp (10.6%)
UR60 No clinical significance 102
Staphylococcus epidermidis (27.0%), Ferruginibacter sp. (14.7%), 
Corynebacterium aurimucosum (11.1%), Methylobacterium 
jeotgaliv (10.6%), Acidobacteria (8.8%), Dokdonella fugitiva (5.2%), 
Methylobacterium oryzae (5.1%), Paracoccus marinus (4.0%), Marmoricola 
aurantiacus (3.4%), Flavobacteriaceae (2.6%), Bacteroides ureolyticus 
(1.6%), Nocardioides sp. (1.0%), Ferruginibacter sp. (0.9%), Pelomonas 
saccharophila (0.8%), Ferruginibacter sp. (0.8%), Propionibacterium acnes 
(0.7%), Campylobacter ureolyticus (0.6%), Gemmatimonadetes (0.4%), 
Niabella sp. (0.4%), Corynebacterium tuberculostearicum (0.3%),
Table 1. Bacterial identification results from 60 urine samples based on culture and NGS of 16S-23S rRNA 
region. AStains revealed different resistance patterns.
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analysis of large datasets requires a combination of bioinformatics skills and computational resources that is 
nowadays mostly absent in diagnostic (medical) microbiological laboratories. Furthermore, metagenomics 
approaches are time consuming as the turnaround time is approximately 4–5 days. To fill the gap between the 
conventional methods (culture and PCR) and metagenomics, a culture free approach using targeted NGS will be 
an excellent approach to detect and identify bacterial species as, compared to metagenomics, it is less complicated, 
and cheaper and therefore more likely to get implemented in diagnostic laboratories within a short timeframe.
The aim of the present study was to develop a rapid and easy-to use culture free diagnostic method based on 
NGS of PCR amplification products encompassing the whole 16S-23S rRNA region to improve the resolution of 
bacterial species identification. Moreover, the new method was compared with three commonly used identifica-
tion methods. Finally, the feasibility of the new identification method to detect and identify bacterial species in 
clinical specimens was evaluated.
Results
Comparison of identification potential of the tested methods. The results of bacterial identification 
obtained by the four tested methods are shown in Supplementary Table S1. The rates of accurate identification 
to the species level using NGS of the 16S-23S rRNA region, Sanger sequencing of the 16S rRNA gene, Microflex 
MS and Vitek MS methods were 92.5%, 56.7%, 73.1% and 64.2%, respectively. The rates of accurate identification 
to the genus level using NGS of the 16S-23S rRNA region, Sanger sequencing of the 16S rRNA gene, Microflex 
MS and Vitek MS methods were 100%, 94.0%, 88.1% and 83.6%, respectively. At the species and genus level, 
assessment of the statistical significance of the differences in accuracy of the four methods for assigning species 
and genus showed statistically significant differences between NGS of the 16S-23S rRNA region versus all other 
tested methods for all bacterial isolates (P < 0.05). The only exception was observed between the two sequencing 
methods at the genus level (P = 0.2482). Moreover, the Sanger sequencing of the 16S rRNA gene was significantly 
more discriminative at the genus level than Vitek MS (P < 0.05).
NGS of 16S-23S rRNA region was the only method which correctly identified to the species level Shigella 
sonnei, Streptococcus oralis, Streptococcus mitis, Streptococcus vestibularis, Abiotrophia para-adiacens and 
Sample Patient Material Culture NGS of 16–23S rRNA region (% of total reads)
KM1 Patient A biopsy (tissue) Negative Propionibacterium acnes (9.1%)A, Haemophilus parainfluenzae (2.3%), eukaryotic DNA (88.6%)
KM2 Patient A punctate (fluid) Negative eukaryotic DNA (100%)
KM3 Patient A punctate (fluid) Negative Sediminibacterium salmoneum (0.3%), eukaryotic DNA (99.7%)
KM4 Patient A punctate (fluid) Negative Gemella sanguinis (1.3%), Haemophilus parainfluenzae (1.0%), eukaryotic DNA (97.7%)
KM5 Patient A punctate (fluid) Negative Herminiimonas sp. (10.5%), Propionibacterium acnes (9.7%)
A, Moraxella catarrhalis (7.5%), eukaryotic 
DNA (72.3%)
KM6 Patient B pus Negative Streptococcus intermedius (100%)
KM7 Patient C biopsy (tissue) Negative eukaryotic DNA (100%)
KM8 Patient C biopsy (tissue) Negative No identification
KM9 Patient D joint puncture (fluid) Negative
Enhydrobacter aerosaccus (49.8%)B, Acinetobacter septicus (18.1%)B, Moraxella osloensis (14.0%), 
Staphylococcus sp. (5.8%), Rheinheimera soli (3.1%), Staphylococcus epidermidis (2.6%), Psychrobacter 
sp. (2.4%)B, Propionibacterium acnes (1.3%)A, Alkanindiges sp. (0.6%), Acinetobacter sp. (0.4%)B, 
Chryseobacterium sp. (0.3%)B
KM10 Patient D joint puncture (fluid) Negative No identification.
KM11 Patient D biopsy (tissue) Negative Propionibacterium acnes (9.8%)
A, Bacillus nealsonii (6.7%)B, Pseudomonas fluorescens (0.6%)A, eukaryotic 
DNA (82.9%)
KM12 Patient D biopsy (tissue) Negative eukaryotic DNA (100%)
KM13 Patient D biopsy (tissue) Negative Undibacterium oligocarboniphilum (3.5%)B, Propionibacterium acnes (0.7%)A, eukaryotic DNA (95.9%)
KM14 Patient D biopsy (tissue) Negative Propionibacterium acnes (1.4%)A, eukaryotic DNA (98.6%)
KM15 Patient D biopsy (tissue) Negative Veillonella parvula (0.9%), eukaryotic DNA (99.1%)
KM16 Patient D biopsy (tissue) Negative eukaryotic DNA (100%)
KM17 Patient E blood n.d. Bacillus cereus (0.5%)B, eukaryotic DNA (99.5%)




n.d. Propionibacterium acnes (64.4%)A, Staphylococcus epidermidis (25.4%), Paracoccus sanguinis (10.1%)B




n.d. Staphylococcus epidermidis (36.0%), Propionibacterium acnes (34.6%)A, Pseudomonas fluorescens (29.4%)A
KM20 Patient F joint puncture (fluid) Negative eukaryotic DNA (100%)
KM21 Patient F biopsy (tissue) Negative Acinetobacter sp. (18.6%)
B, Paucibacter sp. (12.8%), Herminiimonas arsenicoxydans (5.2%), eukaryotic 
DNA (63.4%)
Table 3. Bacterial identification results from 21 clinical orthopedic samples based on culture and NGS of 16S-
23S rRNA region. ASpecies present in negative control(s) and regarded as contamination introduced during 
sample preparation. BGenus absent in negative controls but previously reported as contamination of DNA 
extraction kits, PCR and other laboratory reagents10.
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Sample (Growth CFU/ml) Identification
Detection 
Frequency (n) Average (% reads) Range (% reads)B SDB
UR12 (103) Proteus mirabilis 3 90.0 75.5–97.9 12.6
Proteus vulgaris 3 6.8 0.6–17.5 9.3
Aerococcus urinae 3 1.3 1.1–1.5 0.2
Undibacterium oligocarboniphilumA 1 4.8 n.a. n.a.
Corynebacterium striatum 1 0.3 n.a. n.a.
Pseudomonas saccharophila 1 0.3 n.a. n.a.
Enterococcus faecalis 1 0.2 n.a. n.a.
Ralstonia pickettiiA 1 0.1 n.a. n.a.
UR14 (102) Unidentified species 3 23.6 5.3–42.0 18.4
Peptoniphilus lacrimalis 3 17.9 5.9–33.7 14.3
Fenollaria massiliensis 3 13.5 11.6–15.6 2.0
Peptostreptococcus anaerobius 3 9.5 4.4–13.1 4.5
Mobiluncus curtisii 3 6.0 2.1–10.6 4.3
Anaerococcus sp. 3 3.6 1.8–6.6 2.6
Atopobium deltae 3 2.8 2.3–3.7 0.8
Dialister propionicifaciens 3 0.8 0.6–1.2 0.3
Jonquetella anthropi 3 0.6 0.3–1.1 0.4
Tissierella sp. 2 2.3 2.0–2.6 0.4
Moryella sp. 2 0.8 0.1–1.4 0.9
Fusobacterium nucleatum 2 0.5 0.3–0.7 0.3
Ezakiella sp. 2 0.2 0.1–0.2 0.1
Undibacterium oligocarboniphilumA 1 36.4 n.a. n.a.
Peptoniphilus koenoeneniae 1 4.1 n.a. n.a.
Prevotella bivia 1 3.4 n.a. n.a.
Pseudomonas saccharophila 1 3.1 n.a. n.a.
Candidatus Peptoniphilus massiliensis 1 2.6 n.a. n.a.
Peptoniphilus harei 1 1.1 n.a. n.a.
Streptococcus anginosus 1 0.8 n.a. n.a.
Ralstonia pickettiiA 1 0.7 n.a. n.a.
Methylobacterium oryzaeA 1 0.6 n.a. n.a.
Streptococcus sp. 1 0.6 n.a. n.a.
Asinibacterium lactis 1 0.5 n.a. n.a.
Olsenella sp. 1 0.5 n.a. n.a.
Methylobacterium jeotgaliA 1 0.4 n.a. n.a.
Peptoniphilus duerdenii 1 0.4 n.a. n.a.
Filifactor sp. 1 0.2 n.a. n.a.
Proteus mirabilis 1 0.2 n.a. n.a.
Actinotignum sp. 1 0.2 n.a. n.a.
Bacteroides sp. 1 0.2 n.a. n.a.
Shigella flexneri 1 0.1 n.a. n.a.
Casaltella sp. 1 0.1 n.a. n.a.
Howardella sp. 1 0.1 n.a. n.a.
Propionibacterium acnes 1 0.1 n.a. n.a.
UR22 (102) Lactobacillus crispatus 3 92.8 78.5–100 12.4
Undibacterium oligocarboniphilumA 1 14.4 n.a. n.a.
Pseudomonas saccharophila 1 2.3 n.a. n.a.
Undibacterium ligocarboniphilumA 1 1.5 n.a. n.a.
Unidentified species 1 1.3 n.a. n.a.
Ralstonia pickettiiA 1 1.0 n.a. n.a.
Asinibacterium lactis 1 0.4 n.a. n.a.
Lactobacillus vaginalis 1 0.3 n.a. n.a.
Staphylococcus capitis 1 0.2 n.a. n.a.
Methylobacterium oryzaeA 1 0.1 n.a. n.a.
UR67 (105) Escherichia coli 3 66.1 62.4–70.1 3.9
Aerococcus urinae 3 26.8 22.5–29.5 3.8
Continued
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Achromobacter marplatensis (Table S1). Sanger sequencing of 16S rRNA gene was the only method which did 
not have a potential to identify Corynebacterium ulcerans, Escherichia coli, Enterococcus faecium, Streptococcus 
parasanguinis, Staphylococcus aureus, Staphylococcus capitis, Staphylococcus epidermidis, Lactobacillus rhamno-
sus, Delftia acidovorans and Klebsiella pneumoniae. Vitek MS showed identical and Bruker MS almost identical 
potential compared to NGS of the 16S-23S rRNA region for identification of the Staphylococcus isolates to the 
species level. Moreover, Bruker MS was the only method which correctly identified B. cereus and L. paraca-
sei to the species level, and Pseudomonas aeruginosa was identified only by Vitek MS. Both Mass Spectrometry 
methods could not identify Acinetobacter bereziniae, Corynebacterium afermentans, Corynebacterium pseudo-
genitalium, Salmonella enterica, Streptococcus tigurinus and Moraxella lacunata. Moreover, Vitek MS could not 
identify Acinetobacter parvus, Acinetobacter baumannii, Corynebacterium amycolatum, Corynebacterium coyleae, 
Streptococcus dysgalactiae and Actinomyces graevenitzii, and Bruker MS had a problem with identification of 
Staphylococcus lentus to the species level. No method could unambiguously identify S. pasteuri to the species level 
(Table S1).
Urine samples. Sixty fresh urine samples from patients suspected for urinary tract infections (UTIs) were 
subjected to conventional culture-based methods and culture-independent NGS of the 16S-23S rRNA region. 
Bacterial culture reported the growth of predominant one or two microorganisms at ≥104 CFU/ml as possible 
cause of the suspected UTI. Growth of <104 CFU/ml or growth without predominant microorganism was con-
sidered inconclusive for UTI. NGS of the 16S-23S rRNA region identified from 1 to 47 different bacterial species 
in each PCR-positive sample (Table 1). There was an observed association between the increasing number of 
bacterial genera/species identified using NGS of 16S-23S rRNA region and decreasing CFU value, median: ≥105 
CFU – 2 species/genera; 104 CFU – 5 species/genera; 103 CFU – 5 species/genera; 102 CFU – 20 species/genera. 
Twenty-nine samples were reported as clinically significant. Among them NGS of 16S-23S rRNA region identi-
fied only one bacterial species in 11 samples (UR34, UR35, UR37-UR44, UR50). In the majority of these cases 
(n = 10) pathogenic species identified by NGS of 16S-23S rRNA region were also identified as the cause of infec-
tion by conventional culture methods. The only exception was sample UR44, for which NGS of the 16S-23S rRNA 
identified solely K. pneumoniae, but culture also identified Proteus mirabilis with 103 CFU/ml. In 12 samples, 
in which 2 or more species were identified by NGS of the 16S-23S rRNA region (UR3-UR5, UR7-UR9, UR33, 
UR46, UR48, UR49, UR53, UR55), contigs representing the culture identified pathogenic species consisted of the 
highest number of reads (53.7–99.1% of all reads). For 3 samples (UR2, UR9, UR59) NGS of the 16S-23S rRNA 
region showed improved identification compared to conventional culture. In sample UR2 conventional identi-
fication showed only the presence of P. mirabilis, however the NGS-based method also revealed the presence of 
the genetically related species; Proteus vulgaris. In the sample UR9, Klebsiella oxytoca was identified by NGS of 
16S-23S rRNA region additionally to E. coli. Colonies produced by these two microorganisms can be difficult 
to distinguish due to similar morphology on agar plates. In the sample UR59 possible misidentification by con-
ventional culture method could occur. In this sample K. pneumoniae was identified by Vitek MS and Klebsiella 
variicola by NGS of 16S-23S rRNA region. It was shown very recently, since K. variicola is closely related to K. 
pneumoniae, it is difficult to distinguish between these two species by commonly used methods, including Vitek 
MS9. In the remaining 4 positive samples (UR1, UR36, UR52 and UR54) bacterial species that were identified 
by conventional culture methods as the cause of infection were also found by the NGS of 16S-23S rRNA method 
but were not predominant. Usually, only contigs containing commensal organisms consisted of higher number of 
reads. The urine samples classified by culture as “no clinical significance” (n = 31) contained numerous bacterial 
species, which probably represented the commensal flora. PCR-negative samples (n = 13) were only those sam-
ples with a growth density of 102 CFU/ml.
Blood stream infections. Among the 23 positive blood culture samples, conventional culture methods 
and the NGS of the 16S-23S rRNA region approach produced the same identifications for 20 samples (Table 2). 
For 3 samples (BC11, 19 and 22) identification of bacterial organisms to the species level was improved by the 
Sample (Growth CFU/ml) Identification
Detection 
Frequency (n) Average (% reads) Range (% reads)B SDB
Enterococcus sp. 3 8.5 7.5–9.2 0.9
UR68 (104) Lactobacillus gasseri 3 55.5 50.9–62.4 6.1
Escherichia coli 3 36.9 34.4–41.8 4.3
Streptococcus pasteurianus 3 5.2 2.3–8.7 3.2
Enterococcus sp. 3 1.0 0.3–2.0 0.9
Veillonella sp. 2 0.2 0.2–0.2 0.0
Unidentified species 1 3.6 n.a. n.a.
Facklamia spA 1 0.2 n.a. n.a.
UR69 (105) Klebsiella pneumoniae 3 77.5 73.1–85.5 6.9
Aerococcus urinae 3 12.8 1.8–25.1 11.7
Actinotignum sanguinis 3 8.6 1.3–21.6 11.3
Lactobacillus crispatus 3 1.0 0.1–2.6 1.4
Table 4. Reproducibility of NGS of the 16S-23S region. ABacterial microorganism previously reported as 
contamination of DNA extraction kits, PCR and other laboratory reagents10. Bn.a., not assigned.
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NGS-based method. In case of sample BC11 conventional culture methods were only able to identify the microor-
ganism to the genus level of Bacteroides. In the other two samples, the contigs representing Streptococcus lutetien-
sis (BC19) and Bacteroides dorei (BC22) showed 99.9% (4283/4284) and 100% (4433/4433) sequence homology, 
respectively, during BLAST analysis of the 16S-23S rRNA region. Only a 16S rRNA sequence for Streptococcus 
infantis was available in the GenBank database showing 95.4% (1413/1481) similarity and for Bacteroides vulgatus 
the whole 16S-23S rRNA region shared only 96.5% (4286/4443) similarity to the obtained contig sequence.
Orthopedic infections. Of the 21 clinical samples of orthopedic patients 18 were found to be culture neg-
ative and three samples were not cultured. In 5 samples (KM2, KM7, KM12, KM16 and KM20) the NGS-based 
method was able to detect only eukaryotic DNA and in 2 samples (KM8 and KM10) it yielded non-interpretable 
results most likely because of template degradation. In the remaining 14 samples the number of microorgan-
isms detected in the orthopedic samples ranged from 1 to 3 different genera/species (Table 3). The only excep-
tion was sample KM9 in which 11 different genera/species were found. In our study, orthopedic samples had a 
low amount of starting material, so they were especially prone to be swamped by the contaminating DNA and 
result in misleading results. All negative controls contained Pseudomonas fluorescens. In a single negative control, 
Propionibacterium acnes was also found. Therefore, in orthopedic samples P. fluorescens (present in KM11 and 
KM19) and P. acnes (KM1, KM5, KM9, KM11, KM13, KM14, KM18 and KM19) were regarded as contami-
nation introduced during sample preparation. Moreover, several bacterial genera previously reported as con-
tamination of DNA extraction kits, PCR and other laboratory reagents were absent in all negative controls but 
present at orthopedic samples, including Acinetobacter, Bacillus, Chryseobacterium, Enhydrobacter, Paracoccus, 
Psychrobacter and Undibacterium10. These bacteria can also be potentially considered as contaminations of the 
16–23S rRNA NGS process introduced during sample processing.
Reproducibility. To assess the reproducibility of the method based on NGS of the 16S-23S rRNA region, 6 
urine samples were used: 2 samples with bacterial count level at 102 CFU/ml, single samples with bacterial count 
levels at 104 and 103 CFU/ml, and 2 samples with bacterial count level at ≥ 105 CFU/ml (Table 4). The samples 
were analyzed in triplicate by 3 different operators, including independent PCR amplification, PCR product puri-
fication, and NGS library preparation. Subsequently, two independent MiSeq sequencing runs were conducted. 
The first replicate of each sample was sequenced in the first run, while the second and third replicate of the tested 
samples were sequenced in parallel in the second run. When an organism identified was represented by 5% or 
more reads in at least one replicate of a sample, this organism was always detected in its remaining two replicates 
(Table 4). The only exception was Undibacterium oligocarboniphilum, previously reported as a contaminant in 
DNA extraction kits, and in PCR and other laboratory reagents10. In the samples with bacterial count level at 
≥105 CFU/ml, the method achieved 100% of reproducibility with respect to the bacterial composition. Moreover, 
in all replicates of a sample with a bacterial count level at ≥103 CFU/ml always the same organism was predomi-
nant and represented by 50.9–100% of reads.
Discussion
As defined in the CLSI guidelines, a species identification can be assigned when the max score is 99% or 
higher and if the sequence similarity between best and second best species are greater than 0.5% using DNA 
target sequencing11. However, species identification using CLSI’s criteria for the 16S rRNA gene sequences 
was often weak because the criteria of distance scores greater than 0.5% to the next closest species was not met 
for most strains. In such instances, only identification to the genus level was feasible. Therefore, Park et al.12  
proposed a modified CLSI (mCLSI) method which was more practical and pragmatic for identification of 
species based on 16S rRNA sequences than the CLSI method. The mCLSI method assigns bacterial species 
when the similarity score is 99% or higher but irrespective of the similarity score differences. In our study, 
we applied the similarity score differences with the next closest species as ≥0.2%, which reflected at least 3 
and 9 nucleotides difference by sequencing the 16S rRNA gene or the 16S-23S rRNA region, respectively. It 
allowed elimination of misidentification of very closely related species like S. oralis and S. mitis (Table S1) 
which in their 16S rRNA gene sequence differ only by 1 nucleotide. Using Sanger sequencing of the 16S rRNA 
gene, species was assigned with the similarity score 99.4% or higher (Table S1). Using NGS of the 16S-23S 
rRNA region, in a great majority of cases (n = 61), species were assigned with a similarity score above 99.2%. 
The exceptional 6 species with lower scores showed a similarity ranging from 96.2% to 98.8%. This could be 
caused by the facts that (i) a limited number of 16S-23S rRNA sequences were available in databases and (ii) 
the CLSI guidelines were developed for comparison of gene sequences and did not include the intergenic 
regions which for some genera can be endowed with higher variation. We believe that with increasing number 
of deposited 16S-23S rRNA sequences, it will be always possible to assign bacterial species with similarity 
scores of 99% or higher.
We assigned bacteria to the genus level by NGS of 16S-23S rRNA region in clinical samples when the simi-
larity score was at least 90%. This value was determined based on the results produced during comparison of the 
four identification methods on pure cultures (Table S1). The 16S-23S rRNA sequence alignments produced the 
lowest identity for second closest match within the same genus for: Actinobaculum 88% (Table S1; sample 6), 
Lactobacillus 89% (sample 30), Corynebacterium 91% (samples 14, 17 and 18). We applied the uniform cut-off 
equal to 90% for all bacteria in clinical samples. However, defining 16S-23S rRNA sequences for all or at least 
majority species within a genus will create interpretive criteria for defining the genus and probably will vary 
according to the queried microorganism.
The 16S-23S rRNA sequences can differ by length even among highly genetically related species. It is caused 
by size variation in 16S-23S rRNA intergenic spacer region (ISR). Staphylococcus aureus clonal complex 75 has 
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been recently renamed as Staphylococcus argenteus and now is a novel species of the Staphylococcus genus13. 
S. argenteus showed identical or nearly identical 16S and 23S rRNA gene sequences to S. aureus but differed sub-
stantially by the ISR length. The scoring system of BLAST had been designed not to allow large gaps. The BLAST 
algorithm produced a set of smaller separate alignments, with the longest alignment encompassing the 23S rRNA 
gene (about 2, 5 kb in size). The lack of an alignment for the full-length sequences allowed distinguishing S. aureus 
from S. argenteus.
In our study all negative controls contained P. fluorescens. We, however, only found this microorganism in 
the orthopedic samples (Table 3) and not in the urine and blood samples (Tables 1 and 2). Orthopedic samples 
were characterized with lower starting microbial material compared to that of the urine and blood samples. This 
showed that the impact of contaminating sequences is greater in low biomass samples. Moreover, P. fluorescens 
had not been associated previously with human infections and its presence can be clearly regarded as contam-
ination. However, in a single negative control, which was introduced to monitor the impact of contaminations 
on identification procedure of the orthopedic samples, P. acnes was also identified. P. acnes is a common human 
skin-associated organism and had been previously shown as the cause of orthopedic infections14, 15. It will be 
highly important to limit the impact of such contaminations as P. acnes during samples handling as this is also a 
clinically significant microorganism and its contribution to an infection can be misinterpreted.
NGS of the 16S-23S rRNA region will provide enhanced information on the presence of microbial DNA 
within a clinically relevant time frame which is necessary for timely and accurate treatment of infections and 
therefore key for proper infection and antibiotic resistance control. Data of this study showed that this method 
correctly identified bacterial species that were identified as the cause of infection by conventional culture meth-
ods. In general, in the culture-positive samples a few additional species/genera per sample were identified by the 
NGS method. However, contigs representing the culture identified pathogenic bacterial species had the highest 
number of sequence reads. To assess the clinical relevance of the identified species/genera in samples with a low 
amount of bacterial DNA, a prospective clinical validation study will be carried out including samples of complex 
patient groups (e.g. orthopedic patients with a clinical suspicion of a prosthetic joint infection) and samples of 
control groups of patients without a clinical suspicion of an infection.
Currently, NGS of the 16S-23S rRNA region suffers from two major limitations. First limitation is a lack of 
reference database with the 16S-23S rRNA sequences and a complementary software allowing easy and reliable 
species identification. Second major limitation of the method is a lack of reference sequences for many bacterial 
species. We currently work on the development of a reference data set for assigning clinically relevant bacterial 
species based on the 16S-23S rRNA sequences. The quality and amount of data accumulated in the databases is 
particularly important for the performance of bacterial identification using sequencing analysis of the 16S-23S 
rRNA region. Also, this lack of reference 16S-23S rRNA sequences in the GenBank database might have poten-
tially introduced bias in the results when comparing 16S rRNA with 16S-23S rRNA sequences.
As a proteomic tool for microbial identification, MALDI-TOF MS is superior to NGS-based methods in 
cost and speed. Currently, the total costs of all reagents and consumables for NGS of 16S-23S rRNA region (not 
including labor) amount to ~70 € per sample with turnaround time of ≤4 days. However, NGS of the 16S-23S 
rRNA region was culture independent and more significantly discriminative at the species and genus level than 
MALDI-TOF MS approaches. Moreover, NGS of 16S-23S rRNA region, unlike all other mass spectrometry meth-
ods described above, can be extremely useful for identification of rare or unknown bacteria and bacteria with 
unusual phenotypic profiles.
In summary, the main objective of the present study was to develop a new diagnostic method based on NGS 
of 16S-23S rRNA region and assess its identification potential. Its resolution power was found to be superior to 
the other identification approaches commonly used in routine clinical microbiology laboratories; moreover, the 
method was easy in use. The method correctly identified urinary tract pathogens and blood stream pathogens 
previously identified as the cause of UTI and blood stream infection (BSI) with conventional culture. NGS of the 
16S-23S rRNA region also showed increased sensitivity in the diagnosis of bacterial microorganisms in sam-
ples collected from patients suspected of orthopedic infections. In the analyzed samples several bacterial species 
had been previously reported as the cause of orthopedic infections, including Haemophilus parainfluenzae16, 
Moraxella osloensis17 and S. epidermidis18. Therefore, we conclude that our approach has the potential to increase 
diagnostic yield and will decrease time to result for detection of unexpected bacterial pathogens and bacterial spe-
cies compared to current methods, thereby improving targeted antibiotic treatment. Furthermore, there is a huge 
potential of this method for detection of bacterial pathogens that can not be cultured at all, due to VNC state or 
due to antibiotics prior to collection of sample. Finally, with our method it will be possible to streamline processes 
in the laboratory and to implement it in several disciplines, like clinical, environmental and veterinary microbi-
ology. However, this approach needs further validation and determination of its sensitivity. Furthermore, studies 
focused on the clinical relevance are necessary for determining the applicability of this NGS-based approach in 
routine diagnostics.
Materials and Methods
Ethics. All procedures were carried out according to guidelines and regulations of Certe concerning the use 
of patient materials for the validation of clinical methods, which are in compliance with the guidelines of the 
Federation of Dutch Medical Scientific Societies (FDMSS). The project was approved by the Certe medical staff 
under project submission 3305-0037. Every patient of the Certe is informed that samples taken may be used 
for research and publication purposes unless they indicate that they do not agree to it. Informed consent was 
obtained from all individuals or their guardians prior to study participation. All samples were used after perform-
ing and completing a conventional microbiological diagnosis and were coded to protect patients confidentiality.
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Bacterial isolates. Pure cultures of 44 difficult to identify clinically bacterial isolates were included. 
Additionally, a selection of 23 isolates was used, including 15 ATCC strains (Table S1).
Clinical samples. Sixty fresh urine samples from patients suspected of urinary tract infections (UTI), 23 
BacT/ALERT (bioMérieux) positive blood culture bottles from patients suspected of BSI and 21 clinical samples 
of orthopedic patients were collected. Culture was performed as part of routine diagnostics by the department of 
Bacteriology at Certe.
Vitek MS (bioMérieux). Vitek MS slides were prepared and interpreted according to the manufacturer’s 
instructions. Strains which did not yield an identification due to unreliable results or bad spectra were repeated 
once.
Bruker MS (Bruker). Bruker Microflex slides were prepared using on-slide extraction and interpreted 
according to manufacturer’s instructions. Strains which did not yield an identification due to unreliable results or 
bad spectra were repeated once.
Bacterial isolates DNA extraction. Blood agar plates were used for culturing the bacterial strains. DNA 
isolation from pure cultures was performed using the UltraClean Microbial DNA Isolation Kit (Mobio) according 
to the manufacturer’s instructions.
Urine DNA extraction. DNA isolation of urine samples was performed using the UltraClean Microbial 
DNA Isolation Kit (Mobio). Briefly, 500 µl of urine was centrifuged for 30 seconds at 10,000 g. The supernatant 
was discarded and the pellet reconstituted in 300 µl Microbead solution. Since then the manufacturer’s instruc-
tions were followed for DNA extraction.
Blood culture bottle DNA extraction. DNA from 1.8 ml from positive blood culture bottles was extracted 
using the BiOstic Bacteraemia DNA Isolation Kit (Mobio) according to the manufactures instructions.
DNA extraction of the clinical samples of orthopedic patients. The Purelink Genomic DNA purifi-
cation kit (Invitrogen) was used for DNA extraction of the orthopedic samples. Initial lysis was performed using 
lysis buffer (0.25 M NaCl, 0.5% SDS, 5x TE, 2.25 U/ml Proteinase K (Roche)). For tissue samples a small piece was 
digested in 200 µl lysis buffer. For fluidic samples 200 µl was added to 200 µl lysis buffer. Digestion was performed 
in a thermoshaker at 56 °C under light shaking for 18 hours. 200 µl Purelink Genomic lysis/binding buffer was 
added to 200 µl of lysed sample and vortexed to create a homogenous solution. 200 µl 96% ethanol was added and 
the DNA purification protocol was followed according to the manufacturer’s instructions.
16S rRNA gene amplification and Sanger sequencing. The DNA of the bacterial isolates and controls 
were amplified with 0.3 μM primers [LPW57 5′-AGTTTGATCCTGGCTCAG-3′ (nucleotide position 10–27) 
and LPW58 5′-AGGCCCGGGAACGTATTCAC-3′ (nucleotide position 1370–1389)]19 using GoTaq® MDx Hot 
Start Polymerase and Colorless GoTaq® Flexi Buffer (Promega). PCR amplification was performed on a PTC-100 
thermocycler (Bio-Rad) using the following conditions: an initial incubation at 94 °C for 2 min, 25 cycles of 94 °C 
for 30s, 58 °C for 30s, and 72 °C for 1 min, followed by a final incubation at 72 °C for 5 min. PCR products were 
purified using DNA Clean & Concentrator (Zymo Research). DNA sequencing was performed by the GATC 
company (Cologne, Germany) using the PCR primers. 16S rRNA gene sequences were subjected to BLAST anal-
ysis against the NCBI nucleotide database. The sequencing data analysis allowed assigning species when the 
similarity score was 99% or higher and the similarity score differences with the next closest species were equal to 
or greater than 0.2%, which reflected 3 or more nucleotides. The genus was assigned when the similarity score was 
97% or higher. The BLAST analysis of the 16S rRNA gene sequences was verified against the curated leBiBi-QBPP 
database (https://umr5558-bibiserv.univ-lyon1.fr/lebibi/lebibi.cgi) not revealing any differences in identification.
Amplification of the 16S-23S rRNA region. The 16S-23S rRNA region was amplified by PCR using 
forward primer 27F (5′-AGAGTTTGATCMTGGCTCAG-3′), specific for the 16S rRNA gene and adapted from 
the study by Sergeant et al.20, and reverse primer 2490R (5′-GACATCGAGGTGCCAAAC-3′), specific for the 
23S rRNA gene and slightly modified by truncation of a single nucleotide compared to the original publica-
tion by Hunt et al.21. The amplification of the 16S-23S DNA region was carried out in a 25 µl reaction consist-
ing of 1x Phire hotstart buffer (Thermofisher), 5 mM dNTP’s (Roche), 0.5 µl Phire hotstart II DNA polymerase 
(Thermofisher), 600 nM of each primer and 5 µl of DNA template. PCR was performed using a Biorad PTC-200 
thermocycler. An initial denaturation of 98 °C at 30 sec was followed by 25 cycles of 98 °C for 30 sec, 66 °C for 
30 sec and 72 °C for 2 minutes with a final extension of 72 °C for 1 min. To increase PCR sensitivity in clinical sam-
ples the number of cycles was increased to 35. PCR products were purified using the Qiaquick PCR purification 
kit (Qiagen) according to the manufacturer’s instructions.
NGS library preparation and Illumina MiSeq sequencing. For library preparation, the Nextera XT 
DNA Sample Preparation Kit (Illumina) was used according to the manufacturer’s instructions. Briefly, the puri-
fied PCR amplicons quantified with a Qubit 2.0 Fluorometer (Thermofisher) were diluted to 0.2 ng/µl and a total 
of 1 ng of DNA was tagmented at 55 °C for 5 min. PCR amplification to introduce Illumina index sequences was 
performed in PCR strip tubes in a BioRad T100 thermocycler. Size distribution of fragments was estimated with 
a 2200 TapeStation using the Agilent D1000 High Sensitivity kit according to the manufacturer’s instructions. 
Fragments of 200 to 1000 bp were obtained. The library DNA fragments were size selected and purified using 
AMPure XP beads (Beckman Coulter, Inc.). The indexed libraries were normalized, pooled and loaded onto an 
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Illumina MiSeq reagent cartridge using MiSeq reagent kit v3 and 600 cycles. The paired-end 2 × 300 bp sequenc-
ing was run on an Illumina MiSeq sequencer.
Sequencing of the 16S-23S rRNA region and data analysis. NGS generated 25,000–50,000 or 1–2 
million sequencing reads for pure culture or clinical sample, respectively, to obtain a minimum coverage of 1000 
per sample. The 300-nucleotide paired-end reads were de novo assembled into contigs with the SeqMan NGen 
software (DNASTAR) using parameters: mer size 31 nucleotides and minimum match percentage 93%. The sizes 
of resulting contigs produced during analysis of pure cultures ranged from 4183 bp (Bacillus cereus) up to 4856 bp 
(Acinetobacter parvus) with an average size of 4423 bp (Table S1). In case of clinical samples, most often an iden-
tified bacterial species/genus was represented by a single contig of expected size, around 4.5 kb. However, in some 
instances only smaller contigs (ranging between 1 and 3 kb in size) represented the same bacterial species/genus 
present in a sample. In those cases all contigs belonging to the same organism were combined and their reads 
were added up. Species identification was based on alignment of contig sequences with 16S-23S rRNA sequences 
deposited in the GenBank database using nucleotide BLAST (Basic Local Alignment Search Tool, http://www.
ncbi.nlm.nih.gov/BLAST/). When a reference 16S-23S rRNA sequence was not available in the database, a refer-
ence 16S rRNA gene sequence was used for a species identification. The contig sequences were submitted via the 
website and bacterial species was assigned when the similarity score was 99% or higher and the similarity score 
differences of the first match with the next closest species was equal to or greater than 0.2%. This reflected a 9 or 
more nucleotides difference for a sequence of 4423 bp (the average size of the 16S-23S rRNA amplicon). When 
the similarity score was between 90% and 99%, the genus could be assigned. The score below 90% was interpreted 
as an unidentified organism.
Statistical analysis. The four bacterial identification methods were compared using McNemar’s test, a test 
of paired proportions. Only a single strain per species was taken (from Table S1) for calculation of the accuracy of 
bacterial identification at the species or genus level according to McNemar’s test. When the P value was less than 
0.05, we concluded that there was a significant difference between the methods. Statistical analysis was performed 
using the GraphPad software.
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